|
1
|
Webster AC, Nagler EV, Morton RL and Masson P: Chronic kidney disease. Lancet. 389:1238–1252. 2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Docherty NG, O'Sullivan OE, Healy DA, Fitzpatrick JM and Watson RWG: Evidence that inhibition of tubular cell apoptosis protects against renal damage and development of fibrosis following ureteric obstruction. Am J Physiol Renal Physiol. 290:F4–F13. 2006.PubMed/NCBI View Article : Google Scholar
|
|
3
|
García-Sánchez O, López-Hernández FJ and López-Novoa JM: An integrative view on the role of TGF-beta in the progressive tubular deletion associated with chronic kidney disease. Kidney Int. 77:950–955. 2010.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Maekawa H and Inagi R: Stress signal network between hypoxia and ER stress in chronic kidney disease. Front Physiol. 8(74)2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ruiz S, Pergola PE, Zager RA and Vaziri ND: Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease. Kidney Int. 83:1029–1041. 2013.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Vanholder R, Fouque D, Glorieux G, Heine GH, Kanbay M, Mallamaci F, Massy ZA, Ortiz A, Rossignol P, Wiecek A, et al: Clinical management of the uraemic syndrome in chronic kidney disease. Lancet Diabetes Endocrinol. 4:360–373. 2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Nigam SK and Bush KT: Uraemic syndrome of chronic kidney disease: Altered remote sensing and signalling. Nat Rev Nephrol. 15:301–316. 2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Yang Q, Su S, Luo N and Cao G: Adenine-induced animal model of chronic kidney disease: Current applications and future perspectives. Ren Fail. 46(2336128)2024.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Gava AL, Freitas FP, Balarini CM, Vasquez EC and Meyrelles SS: Effects of 5/6 nephrectomy on renal function and blood pressure in mice. Int J Physiol Pathophysiol Pharmacol. 4:167–173. 2012.PubMed/NCBI
|
|
10
|
Chen CH, Sue YM, Cheng CY, Chen YC, Liu CT, Hsu YH, Hwang PA, Huang NJ and Chen TH: Oligo-fucoidan prevents renal tubulointerstitial fibrosis by inhibiting the CD44 signal pathway. Sci Rep. 7(40183)2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Li LC, Chen WY, Chen JB, Lee WC, Chang CC, Tzeng HT, Huang CC, Chang YJ and Yang JL: The AST-120 recovers uremic toxin-induced cognitive deficit via NLRP3 inflammasome pathway in astrocytes and microglia. Biomedicines. 9(1252)2021.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Gong W, Mao S, Yu J, Song J, Jia Z, Huang S and Zhang A: NLRP3 deletion protects against renal fibrosis and attenuates mitochondrial abnormality in mouse with 5/6 nephrectomy. Am J Physiol Renal Physiol. 310:F1081–F1088. 2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Montes-Rivera JO, Tamay-Cach F, Quintana-Pérez JC, Guevara-Salazar JA, Trujillo-Ferrara JG, Del Valle-Mondragón L and Arellano-Mendoza MG: Apocynin combined with drugs as coadjuvant could be employed to prevent and/or treat the chronic kidney disease. Ren Fail. 40:92–98. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Yu J, Mao S, Zhang Y, Gong W, Jia Z, Huang S and Zhang A: MnTBAP therapy attenuates renal fibrosis in mice with 5/6 nephrectomy. Oxid Med Cell Longev. 2016(7496930)2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Liu Y and Wang Y, Ding W and Wang Y: Mito-TEMPO alleviates renal fibrosis by reducing inflammation, mitochondrial dysfunction, and endoplasmic reticulum stress. Oxid Med Cell Longev. 2018(5828120)2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Ding W, Wang B, Zhang M and Gu Y: Tempol, a superoxide dismutase-mimetic drug, ameliorates progression of renal disease in CKD mice. Cell Physiol Biochem. 36:2170–2182. 2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Imafuku T, Watanabe H, Satoh T, Matsuzaka T, Inazumi T, Kato H, Tanaka S, Nakamura Y, Nakano T, Tokumaru K, et al: Advanced oxidation protein products contribute to renal tubulopathy via perturbation of renal fatty acids. Kidney360. 1:781–796. 2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Lu CW, Lee CJ, Hsieh YJ and Hsu BG: Empagliflozin attenuates vascular calcification in mice with chronic kidney disease by regulating the NFR2/HO-1 anti-inflammatory pathway through AMPK activation. Int J Mol Sci. 24(10016)2023.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Tseng KF, Tsai PH, Wang JS, Chen FY and Shen MY: Sesamol attenuates renal inflammation and arrests reactive-oxygen-species-mediated IL-1β secretion via the HO-1-induced inhibition of the IKKα/NFκB pathway in vivo and in vitro. Antioxidants (Basel). 11(2461)2022.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Stadler K, Goldberg IJ and Susztak K: The evolving understanding of the contribution of lipid metabolism to diabetic kidney disease. Curr Diab Rep. 15(40)2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Szeto HH: Pharmacologic approaches to improve mitochondrial function in AKI and CKD. J Am Soc Nephrol. 28:2856–2865. 2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Li J, Xiang T, Zhang F, Feng L, Wu Y, Guo F, Li L, Fu P and Ma L: Tubular ACSM3 deficiency impairs medium-chain fatty acid metabolism and aggravates kidney fibrosis. Proc Natl Acad Sci USA. 122(e2505752122)2025.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Venn-Watson S, Lumpkin R and Dennis EA: Efficacy of dietary odd-chain saturated fatty acid pentadecanoic acid parallels broad associated health benefits in humans: Could it be essential? Sci Rep. 10(8161)2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Sasaki K, Geribaldi-Doldán N, Wu Q, Davies J, Szele FG and Isoda H: Microalgae Aurantiochytrium Sp. Increases neurogenesis and improves spatial learning and memory in senescence-accelerated mouse-prone 8 mice. Front Cell Dev Biol. 8(600575)2021.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Takahashi S, Yoshida M, Watanabe MM and Isoda H: Anti-inflammatory effects of Aurantiochytrium limacinum 4W-1b ethanol extract on murine macrophage RAW264 cells. Biomed Res Int. 2019(3104057)2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Kaneko H, Sakakida K, Kaya K, Tsuboi M, Sakata Y, Sakamoto S, Wei FY and Tomizawa K: Improvement of glucose intolerance in Asian-type diabetes model mice using pentadecyl, pentadecanoic acid-based triglyceride. Diabetes Obes Int J. 8:1–7. 2023.
|
|
27
|
Tsuruta K, Sato Y, Nango H, Sakata Y, Ishikawa H, Tsuboi M, Miyagishi H and Kosuge Y: Pentadecyl®, an odd-chain-rich triglyceride mixture derived from Aurantiochytrium oil, attenuates lipopolysaccharide-induced inflammatory cytokine production in BV-2 microglial cells. Int Immunopharmacol. 158(114810)2025.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Shimizu H, Yisireyili M, Nishijima F and Niwa T: Stat3 contributes to indoxyl sulfate-induced inflammatory and fibrotic gene expression and cellular senescence. Am J Nephrol. 36:184–189. 2012.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Kawakami T, Inagi R, Wada T, Tanaka T, Fujita T and Nangaku M: Indoxyl sulfate inhibits proliferation of human proximal tubular cells via endoplasmic reticulum stress. Am J Physiol Renal Physiol. 299:F568–F576. 2010.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Levin A, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, Herrington WG, Hill G, Inker LA, Kazancıoğlu R, et al: Executive summary of the KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease: Known knowns and known unknowns. Kidney Int. 105:684–701. 2024.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Hashimoto N, Sakaguchi Y, Hattori K, Kawano Y, Kawaoka T, Doi Y, Oka T, Kusunoki Y, Yamamoto S, Yamato M, et al: Discontinuing renin-angiotensin system inhibitors after incident hyperkalemia and clinical outcomes: target trial emulation. Hypertens Res. 48:2034–2044. 2025.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Perrin P, Muller C, Dimitrov Y, Chantrel F, Heitz M, Woerly A, Bazin D, Faller AL, Krummel T and Hannedouche T: Assessment of SGLT2 inhibitors' safety and discontinuation causes in patients with advanced chronic kidney disease: Insights from a real-world data analysis. Clin Kidney J. 17(sfae169)2024.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Chopra B and Dhingra AK: Natural products: A lead for drug discovery and development. Phytother Res. 35:4660–4702. 2021.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Robinson MK, Lee E, Ugalde-Nicalo PA, Skonieczny JW, Chun LF, Newton KP and Schwimmer JB: Pentadecanoic acid supplementation in young adults with overweight and obesity: A randomized controlled trial. J Nutr. 154:2763–2771. 2024.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group: KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 105 (4S):S117–S314. 2024.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Levey AS, Inker LA, Matsushita K, Greene T, Willis K, Lewis E, de Zeeuw D, Cheung AK and Coresh J: GFR decline as an end point for clinical trials in CKD: A scientific workshop sponsored by the national kidney foundation and the US food and drug Administration. Am J Kidney Dis. 64:821–835. 2014.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Rende U, Guller A, Goldys EM, Pollock C and Saad S: Diagnostic and prognostic biomarkers for tubulointerstitial fibrosis. J Physiol. 601:2801–2826. 2023.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Shao D, Jimenez AL, Guerrero MS, Wang S and Broder A: Factors associated with worsening interstitial fibrosis/tubular atrophy in lupus nephritis patients undergoing clinically indicated repeat kidney biopsy. BMC Nephrol. 26(189)2025.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Hommos MS, Zeng C, Liu Z, Troost JP, Rosenberg AZ, Palmer M, Kremers WK, Cornell LD, Fervenza FC, Barisoni L and Rule AD: Global glomerulosclerosis with nephrotic syndrome; the clinical importance of age adjustment. Kidney Int. 93:1175–1182. 2018.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Kosuge Y, Osada N, Shimomura A, Miyagishi H, Wada T, Ishige K, Shimba S and Ito Y: Relevance of the hippocampal endoplasmic reticulum stress response in a mouse model of chronic kidney disease. Neurosci Lett. 677:26–31. 2018.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Osada N, Kosuge Y, Kihara T, Ishige K and Ito Y: Apolipoprotein E-deficient mice are more vulnerable to ER stress after transient forebrain ischemia. Neurochem Int. 54:403–409. 2009.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Nakada Y, Onoue K, Nakano T, Ishihara S, Kumazawa T, Nakagawa H, Ueda T, Nishida T, Soeda T, Okayama S, et al: AST-120, an oral carbon absorbent, protects against the progression of atherosclerosis in a mouse chronic renal failure model by preserving sFlt-1 expression levels. Sci Rep. 9(15571)2019.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Palacios-Ramirez R, Lima-Posada I, Bonnard B, Genty M, Fernandez-Celis A, Hartleib-Geschwindner J, Foufelle F, Lopez-Andres N, Bamberg K and Jaisser F: Mineralocorticoid receptor antagonism prevents the synergistic effect of metabolic challenge and chronic kidney disease on renal fibrosis and inflammation in mice. Front Physiol. 13(859812)2022.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Medipally A, Xiao M, Satoskar AA, Biederman L, Dasgupta A, Ivanov I, Mikhalina G, Rovin B and Brodsky SV: N-acetylcysteine ameliorates hematuria-associated tubulointerstitial injury in 5/6 nephrectomy mice. Physiol Rep. 11(e15767)2023.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Mak RH, Ikizler AT, Kovesdy CP, Raj DS, Stenvinkel P and Kalantar-Zadeh K: Wasting in chronic kidney disease. J Cachexia Sarcopenia Muscle. 2:9–25. 2011.
|
|
46
|
Cheng TC, Huang SH, Kao CL and Hsu PC: Muscle wasting in chronic kidney disease: Mechanism and clinical implications-A narrative review. Int J Mol Sci. 23(6047)2022.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Kim K, Anderson EM, Thome T, Lu G, Salyers ZR, Cort TA, O'Malley KA, Scali ST and Ryan TE: Skeletal myopathy in CKD: A comparison of adenine-induced nephropathy and 5/6 nephrectomy models in mice. Am J Physiol Renal Physiol. 321:F106–F119. 2021.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Clark WF, Sontrop JM, Huang SH, Gallo K, Moist L, House AA, Weir MA and Garg AX: The chronic kidney disease water intake trial (WIT): Results from the pilot randomised controlled trial. BMJ Open. 3(e003666)2013.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Sontrop JM, Dixon SN, Garg AX, Buendia-Jimenez I, Dohein O, Huang S-HS and Clark WF: Association between water intake, chronic kidney disease, and cardiovascular disease: A cross-sectional analysis of NHANES data. Am J Nephrol. 37:434–442. 2013.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Bouby N, Bachmann S, Bichet D and Bankir L: Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat. Am J Physiol. 258:F973–F979. 1990.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Gibb IA and Hamilton DN: An experimental model of chronic renal failure in mice. Clin Immunol Immunopathol. 35:276–284. 1985.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Mazzaccara C, Labruna G, Cito G, Scarfò M, De Felice M, Pastore L and Sacchetti L: Age-related reference intervals of the main biochemical and hematological parameters in C57BL/6J, 129SV/EV and C3H/HeJ mouse strains. PLoS One. 3(e3772)2008.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Suh SH and Kim SW: Dyslipidemia in patients with chronic kidney disease: An updated overview. Diabetes Metab J. 47:612–629. 2023.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Hamzaoui M, Djerada Z, Brunel V, Mulder P, Richard V, Bellien J and Guerrot D: 5/6 nephrectomy induces different renal, cardiac and vascular consequences in 129/Sv and C57BL/6JRj mice. Sci Rep. 10(1524)2020.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Klapczynski M, Gagne GD, Morgan SJ, Larson KJ, Leroy BE, Blomme EA, Cox BF and Shek EW: Computer-assisted imaging algorithms facilitate histomorphometric quantification of kidney damage in rodent renal failure models. J Pathol Inform. 3(20)2012.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Lopez-Giacoman S and Madero M: Biomarkers in chronic kidney disease, from kidney function to kidney damage. World J Nephrol. 4:57–73. 2015.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Song S, Meyer M, Türk TR, Wilde B, Feldkamp T, Assert R, Wu K, Kribben A and Witzke O: Serum cystatin C in mouse models: A reliable and precise marker for renal function and superior to serum creatinine. Nephrol Dial Transplant. 24:1157–1161. 2009.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Mawhin MA, Bright RG, Fourre JD, Vloumidi EI, Tomlinson J, Sardini A, Pusey CD and Woollard KJ: Chronic kidney disease mediates cardiac dysfunction associated with increased resident cardiac macrophages. BMC Nephrol. 23(47)2022.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Obert LA, Elmore SA, Ennulat D and Frazier KS: A review of specific biomarkers of chronic renal injury and their potential application in nonclinical safety assessment studies. Toxicol Pathol. 49:996–1023. 2021.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Kaya K, Kazama Y, Abe T and Shiraishi F: Influence of medium components and pH on the production of odd-carbon fatty acids by Aurantiochytrium sp. SA-96. J Appl Phycol. 32:1597–1606. 2020.
|
|
61
|
Wu Y, Zhang X, Liu X, Zhao Z, Tao S, Xu Q, Zhao J, Dai Z, Zhang G, Han D and Wang J: Galactooligosaccharides and Limosilactobacillus reuteri synergistically alleviate gut inflammation and barrier dysfunction by enriching Bacteroides acidifaciens for pentadecanoic acid biosynthesis. Nat Commun. 15(9291)2024.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Huang Q, Chen C, Zhang Z and Xue Q: Anti-inflammatory effects of myristic acid mediated by the NF-κB pathway in lipopolysaccharide-induced BV-2 microglial cells. Mol Omics. 19:726–734. 2023.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Bishop CA, Machate T, Henkel J, Schulze MB, Klaus S and Piepelow K: Heptadecanoic acid is not a key mediator in the prevention of diet-induced hepatic steatosis and insulin resistance in mice. Nutrients. 15(2052)2023.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Ma LJ and Fogo AB: Model of robust induction of glomerulosclerosis in mice: Importance of genetic background. Kidney Int. 64:350–355. 2003.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Leelahavanichkul A, Yan Q, Hu X, Eisner C, Huang Y, Chen R, Mizel D, Zhou H, Wright EC, Kopp JB, et al: Angiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant kidney mouse model. Kidney Int. 78:1136–1153. 2010.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Mulay SR, Eberhard JN, Pfann V, Marschner JA, Darisipudi MN, Daniel C, Romoli S, Desai J, Grigorescu M, Kumar SV, et al: Oxalate-induced chronic kidney disease with its uremic and cardiovascular complications in C57BL/6 mice. Am J Physiol Renal Physiol. 310:F785–F795. 2016.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Dai XY, Zhou L, Huang XR, Fu P and Lan HY: Smad7 protects against chronic aristolochic acid nephropathy in mice. Oncotarget. 6:11930–11944. 2015.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Bikbov B, Perico N and Remuzzi G: on behalf of the GBD Genitourinary Diseases Expert Group. Disparities in chronic kidney disease prevalence among males and females in 195 countries: Analysis of the global burden of disease 2016 study. Nephron. 139:313–318. 2018.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Sasaki K, Othman MB, Ferdousi F, Yoshida M, Watanabe M, Tominaga K and Isoda H: Modulation of the neurotransmitter systems through the anti-inflammatory and antidepressant-like effects of squalene from Aurantiochytrium sp. PLoS One. 14(e0218923)2019.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Habshi T, Shelke V, Kale A, Anders HJ and Gaikwad AB: Role of endoplasmic reticulum stress and autophagy in the transition from acute kidney injury to chronic kidney disease. J Cell Physiol. 238:82–93. 2023.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Henedak NT, El-Abhar HS, Soubh AA and Abdallah DM: NLRP3 inflammasome: A central player in renal pathologies and nephropathy. Life Sci. 351(122813)2024.PubMed/NCBI View Article : Google Scholar
|
